Core B: University of Kentucky Alzheimer's Disease Core Center

核心 B：肯塔基大学阿尔茨海默病核心中心

• 批准号: 10459467
• 负责人: GREGORY A JICHA
• 金额: $ 97.56万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10459467
• 关键词: Alzheimer' s Disease; Alzheimer' s Disease Core Center; Alzheimer' s disease related dementia; Area; Automobile Driving; Autopsy; Biological Markers; Brain; Clinic; Clinical; Clinical Trials; Cognitive; Collaborations; Communities; Correlative Study; Dementia; Development; Diagnosis; Disease; Education; Elderly; Enrollment; Ensure; Environment; Etiology; Family; Fostering; Foundations; Funding; Genetic; Goals; Heterogeneity; Image; Individual; Industry; Infrastructure; Intervention; Kentucky; Link; Liquid substance; Longitudinal cohort; Measures; Minority; Minority Groups; Mission; Participant; Pathologic; Pharmaceutical Preparations; Phase; Phenotype; Play; Prevention; Productivity; Publications; Recommendation; Research; Research Personnel; Research Project Grants; Research Support; Role; Syndrome; System; Trademark; United States National Institutes of Health; Universities; Work; base; clinical biomarkers; clinical phenotype; cohort; design; driving force; high risk; innovation; minority engagement; multidisciplinary; normal aging; novel; novel therapeutic intervention; parity; pre-clinical; preclinical study; research clinical testing; success; therapeutic development; translational therapeutics

Project Summary/Abstract: Clinical Core The Clinical Core of the UK-ADRC maintains a well-characterized, community-based cohort focused on normal aging and early transitional disease states and follows individuals longitudinally until brain autopsy. We maintain a mandatory autopsy requirement for all subjects (with the exception of our Minority Gateway Clinic, where autopsy is promoted but not required), allowing major contributions in the area of clinical- pathological correlative studies, and definition of early preclinical and pre-dementia disease states. These efforts have been a driving force in our recognition of the heterogeneity of community-acquired dementia, including major contributions to the field in regard to LATE, PART, VCID, and the role these pathologic states play in conjunction with traditional AD, LBD, and FTLD disease states. A major focus of our work has also been on defining early clinical transitions involving the interplay of these disease states that has driven the widespread exploration of late-life multi-etiology dementia syndromes. To further such advances, the UK-ADRC Clinical Core emphasizes deep clinical, biomarker, genetic, and post-mortem phenotyping of a diverse cohort of elderly subjects at high risk for multi-etiology dementia. Major initiatives in the area of AD mimics and transitions from normal to late-life multi-etiology dementia are well-poised to continue to move the field forward in the areas of both diagnosis and translational interventional discoveries. We have introduced exciting new initiatives in our expansion of antemortem biomarker research allowing an even deeper clinical phenotyping of our participants as we work towards translational discoveries for multi-etiology dementia. The UK-ADRC will continue to constantly evolve in dynamic ways through our proposed specific aims. Aim 1: Maintain & longitudinally characterize a central longitudinal cohort enrolling cognitively normal subjects to facilitate our understanding of preclinical disease and early cognitive transitions to multi-etiology MCI & dementia. Aim 2: Maintain and expand our successful Minority Gateway Clinics to maintain and grow our (significantly) above-parity for population minority engagement. Aim 3: Further develop and maintain an infrastructure to support translational therapeutic development through all clinical trial phases in support of NIH, ADCS, ACTC initiatives, industry-sponsored drug trials, and investigator-initiated projects. Aim 4: Foster education and support of research participants and families to ensure that our efforts are clinically meaningful, both in novel prevention studies as well as treatment in established disease Overall, the Clinical Core will continue to provide an infrastructure and environment that will continue to contribute to our success in advancing multidisciplinary, innovative AD research supporting our center theme of Transitions from Normal to Late-Life Multi-Etiology Dementia.

项目摘要/摘要：临床核心 UK-ADRC 的临床核心维持着一个特征明确、以社区为基础的队列，重点关注 正常衰老和早期过渡性疾病会纵向跟踪个体，直至脑部尸检。 我们对所有受试者保持强制性尸检要求（少数群体网关除外） 诊所，提倡但不要求尸检），允许在临床领域做出重大贡献 病理相关研究，以及早期临床前和痴呆前疾病状态的定义。这些 我们的努力推动了我们认识到社区获得性痴呆的异质性， 包括在 LATE、PART、VCID 方面对该领域的重大贡献，以及这些病理学的作用 状态与传统的 AD、LBD 和 FTLD 疾病状态一起发挥作用。我们工作的一个主要重点是 也一直在定义涉及这些疾病状态相互作用的早期临床转变，这些疾病状态推动了 对晚年多病因痴呆综合征的广泛探索。为了进一步推动此类进步， UK-ADRC 临床核心强调深度临床、生物标志物、遗传和死后表型分析 具有多病因痴呆高风险的不同老年受试者群体。 AD领域的主要举措 从正常到晚年多病因痴呆的模仿和转变已做好准备继续推动 在诊断和转化介入发现领域取得了进步。我们已经介绍了 我们在扩大生前生物标志物研究方面采取了令人兴奋的新举措，从而可以进行更深入的临床研究 当我们致力于多病因痴呆症的转化发现时，对参与者进行表型分析。这 UK-ADRC 将继续通过我们提出的具体目标以动态方式不断发展。 目标 1：维持并纵向描述招募认知正常受试者的中心纵向队列 促进我们对临床前疾病的理解以及向多病因 MCI 的早期认知转变 失智。 目标 2：维持和扩大我们成功的少数族裔门户诊所，以维持和发展我们的（显着） 少数民族人口参与度高于均等。 目标 3：进一步开发和维护基础设施，以支持转化治疗的开发 支持 NIH、ADCS、ACTC 计划、行业赞助的药物试验的所有临床试验阶段，以及 研究者发起的项目。 目标 4：促进对研究参与者和家庭的教育和支持，以确保我们的努力得到落实 无论是在新型预防研究还是已确定疾病的治疗中都具有临床意义 总体而言，临床核心将继续提供基础设施和环境，以继续 为我们成功推进支持我们中心主题的多学科、创新 AD 研究做出贡献 从正常到晚年多病因痴呆的转变。